Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilar

Aurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health Canada for its cancer drug Bevqolva. This approval marks a crucial step for the bevacizumab biosimilar. Bevqolva is used to treat various cancers. Health Canada's nod confirms its safety and efficacy. This opens new avenues for cancer treatment in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4Zb1YWw
via IFTTT

Read More

Drugs at your door: Signs of a disruption taking shape in India

India Pharmacy Retail Quick Commerce: India's medicine delivery is seeing a change. Quick-commerce apps are making it easier to buy medicines regularly. While total sales are not growing much, people are buying more wellness products. Acute care medicines are seeing fewer sales. This shift is happening as more people shop online for health items. The market is changing, not booming yet.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WA1ktfa
via IFTTT

Read More

ORS sales melt in March after govt's stricter labelling norms

India’s oral rehydration solution (ORS) market has declined after regulatory action restricted the labelling of sugary drinks as ORS, affecting pharmaceutical companies that depend on seasonal demand.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1hk20ED
via IFTTT

Read More

RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-September

RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company also aims to enter the GLP-1 weight-loss therapy market by August-September. Despite geopolitical risks, RPG Life Sciences is strategically focusing on niche, complex molecules and expanding into new therapy areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0UcztMm
via IFTTT

Read More

Weight-loss drugs may also help cut alcohol intake: Study

A new study shows GLP-1 drugs like semaglutide may help reduce heavy drinking. A trial found weekly injections cut heavy drinking days by half. This drug, also used for obesity, showed significant results in adults with alcohol use disorder. The findings could impact millions globally. Further research is ongoing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Rw2p4TY
via IFTTT

Read More

KKR invests Rs 1,750 cr in Baby Memorial Hospital

KKR, the prominent US investment firm, has committed another ₹1,750 crore to Baby Memorial Hospital, elevating their overall investment to an impressive ₹5,100 crore in just a short span of two years. This Kozhikode-centered hospital chain is poised for significant regional growth. The capital will facilitate strategic acquisitions and further expansion, now boasting nine hospitals spread across three southern states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/neIgkx6
via IFTTT

Read More

IHH-Daiichi legal battle nears verdict on September 10

A major legal battle between IHH Healthcare and Daiichi Sankyo is reaching its climax. IHH's subsidiary, NTK, is seeking JPY 200 billion in damages. The Tokyo District Court will deliver its judgment on September 10. This ruling follows NTK's allegations of Daiichi Sankyo obstructing its acquisition of Fortis Healthcare shares.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/blz1ODJ
via IFTTT

Read More